Immunological mechanisms of drug-induced liver injury

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 1, 2005, Pages 38-43

  Ju, Cynthia ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Drug induced hepatotoxicity; Drug induced immune reactions; Hapten hypothesis; Immunological tolerance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; AUTOANTIBODY; BENDAZAC; BROMFENAC; CARBAMAZEPINE; DESFLURANE; DICLOFENAC; DIHYDRALAZINE; DROXICAM; DRUG ANTIBODY; EBROTIDINE; HALOTHANE; HAPTEN; ISOFLURANE; LIVER PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; T LYMPHOCYTE RECEPTOR; THIOACETAMIDE; TIENILIC ACID; TOLCAPONE; TRIFLUOROACETIC ACID; TROGLITAZONE; TROVAFLOXACIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG PROTEIN BINDING; EOSINOPHILIA; FATALITY; FEVER; GENETIC POLYMORPHISM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; KUPFFER CELL; LIVER SINUSOID; LIVER TOXICITY; LYMPHOCYTE DIFFERENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MODEL; MOLECULAR WEIGHT; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RASH; REVIEW; RISK FACTOR; TH1 CELL; TH2 CELL;

ANIMALS; HAPTENS; HEPATITIS, TOXIC; HUMANS; IMMUNE TOLERANCE; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 12244312518     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Kaplowitz N: Drug-induced liver disorders: Implications for drug development and regulation. Drug Saf (2001) 24(7):483-490.
2. Ibanez L, Perez E, Vidal X, Laporte JR: Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive or metabolic diseases: Epidemiological and clinical features, and exposure to drugs. J Hepatol (2002) 37(5):592-600.
3. Larrey D: Drug-induced liver diseases. J Hepatol (2000) 32 (1 Suppl):77-88.
4. Pessayre D, Larrey D, Biour M: Drug-induced liver injury. In: Oxford Textbook of Clinical Hepatology. Bircher J, Benhamou J, McIntyre N, Rizzetto M, Rodes J (Eds), Oxford University Press, Oxford, UK (1999):1261-1315.
5. Anonymous: Call for droxicam suspension. Reactions (1995) 1(534):3.
6. Bromfenac withdrawal. WHO Drug Information (1998) 12(3):146. http://www.who.int/druginformation/vol12/12-3.pdf
7. Alert No 72: Withdrawal of medicinal products containing ebrotidine - liver toxicity. World Health Organization, Essential Drugs and Medicines Policy, Geneva, Switzerland (1998). http://www.who.int/medicines/library/qsm/drugalert/ alert72.htm
8. Withdrawal of tolcapone (Tasmar). Curr Probl Pharmacovigilance. Medicines and Healthcare Products Regulatory Agency, London, UK (1999) 25:2. http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/ cpvol25asec2.htm
9. Alert 86: Trovafloxacin and alatrofloxacin - suspension and warnings: Hepatotoxicity. World Health Organization, Essential Drugs and Medicines Policy, Geneva, Switzerland (1999). http://www.who.int/medicines/library/qsm/drugalert/ alert86.htm
10. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L: Drug safety discontinuations in the United Kingdom, the United States and Spain from 1974 through 1993: A regulatory perspective. Clin Pharmacol Ther (1995) 58(1):108-117.
11. Troglitazone (Romozin) withdrawn. Curr Probl Pharmacovigilance. Medicines and Healthcare Products Regulatory Agency, London, UK (1997) 23:13. http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/first. htm#Troglitazone
12. Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI: Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol (1995) 133(1):43-52.
13. Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N: A pivotal involvement of IFN-γ in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J (2002) 16(10):1227-1236.
14. Lawson JA, Fisher MA, Simmons CA, Farhood A, Jaeschke H: Inhibition of Fas receptor (CD95)-induced hepatic caspase activation and apoptosis by acetaminophen in mice. Toxicol Appl Pharmacol (1999) 156(3):179-186.
15. Kaplowitz N: Drug-induced liver injury. Clin Infect Dis (2004) 38(Suppl 2):S44-S48.
16. Zimmerman HJ: Drug-induced liver disease. In: Schiff's Diseases of the Liver. Schiff ER, Sorrell MF, Maddrey WC (Eds), Lippincott-Raven, Philadelphia, PA, USA (1999):973-1064.
17. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E: Allergic and autoimmune reactions to xenobiotics: How do they arise? Immunol Today (1998) 19(3):133-141.
18. Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR: Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci USA (1989) 86(1):322-326.
19. Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston AL, Davis M, Williams R: Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 303(2):66-71.
20. Pohl LR, Kenna JG, Satoh H, Christ D, Martin JL: Neoantigens associated with halothane hepatitis. Drug Metab Rev (1989) 20(2-4):203-217.
21. Bourdi M, Tinel M, Beaune PH, Pessayre D: Interactions of dihydralazine with cytochromes P4501A: A possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol (1994) 45(6):1287-1295.
22. Lecoeur S, Andre C, Beaune PH: Tienilic acid-induced autoimmune hepatitis: Anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol (1996) 50(2):326-333.
23. Nelson SD, Pearson PG: Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu Rev Pharmacol Toxicol (1990) 30:169-195.
24. Uetrecht JP: New concepts in immunology relevant to idiosyncratic drug reactions: The 'danger hypothesis' and innate immune system. Chem Res Toxicol (1990) 12(5):387-395.
25. Gallucci S, Matzinger P: Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 13(1):114-119. Review of studies aimed at identifying endogenous and exogenous danger signals that play an important role in activating dendritic cells and initiating immune reactions.
26. Njoku D, Laster MJ, Gong DH, Eger EI, Reed GF, Martin JL: Biotransformation of halothane, enflurane, isoflurane and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury. Anesth Analg (1997) 84(1):173-178.
27. Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, Binns RM, Davies DA: Induction of immunological tolerance by porcine liver allografts. Nature (1969) 223(205):472-476.
28. Gorczynski RM, Chan Z, Chung S, Cohen Z, Levy G, Sullivan B, Fu XM: Prolongation of rat small bowel or renal allograft survival by pretransplant transfusion and/or by varying the route of allograft venous drainage. Transplantation (1994) 58(7):816-820.
29. Rao VK, Burris DE, Gruel SM, Sollinger HW, Burlingham WJ: Evidence that donor spleen cells administered through the portal vein prolong the survival of cardiac allografts in rats. Transplantation (1988) 45(6):1145-1146.
30. Cantor HM, Dumont AE: Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature (1967) 215(102):744-745.
31. Chen Y, Ong CR, McKenna GJ, Mui AL, Smith RM, Chung SW: Induction of immune hyporesponsiveness after portal vein immunization with ovalbumin. Surgery (2001) 129(1):66-75.
32. Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN: The liver eliminates T-cells undergoing antigen-triggered apoptosis in vivo. Immunity (1994) 1(9):741-749.
33. Bertolino P, Heath WR, Hardy CL, Morahan G, Miller JF: Peripheral deletion of autoreactive CD8+ T-cells in transgenic mice expressing H-2Kb in the liver. Eur J Immunol (1995) 25(7):1932-1942.
34. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T: PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 198(1):39-50. Demonstrates that LSECs and KCs constitutively express PDL-1, which inhibits the proliferation of activated T-cells that express programmed death receptor-1 (PD-1).
35. Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN: Immunomodulatory effects of the liver: Deletion of activated CD4+ effector cells and suppression of IFN-γ-producing cells after intravenous protein immunization. J Immunol (2002) 169(5):2407-2413. Description of the fate of TCR-transgenic Th1 or Th2 CD4+ T-cells after adoptive transfer to mice, demonstrating that the cells accumulate in the liver, and that Th1, but not Th2 cells, lose their capacity to produce cytokines.
36. Knolle PA, Schmitt E, Jin S, Germann T, Duchmann R Hegenbarth S, Gerken G, Lohse AW: Induction of cytokine production in naïve CD4(+) T-cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology (1999) 116(6):1428-1440. This paper, along with reference [37·], demonstrates that LSECs are capable of activating both CD4+ and CD8+ T-cells, although the activated T-cells fail to differentiate into effector cells.
37. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA: Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T-cells results in antigen-specific T-cell tolerance. Nat Med (2000) 6(12):1348-1354. This paper, along with reference [36·], demonstrates that LSECs are capable of activating both CD4+ and CD8+ T-cells, although the activated T-cells fail to differentiate into effector cells.
38. Ju C, McCoy JP, Chung CJ, Graf ML, Pohl LR: Tolerogenic role of Kupffer cells in allergic reactions. Chem Res Toxicol (2003) 16(12):1514-1519.
39. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet (2000) 356(9242):1667-1671.
40. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology (2002) 35(4):883-889.
41. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PS, Rahier J et al: HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology (1999) 117(5):1181-1186. Demonstrates a significant association between an HLA haplotype and drug-induced immune-mediated hepatitis using DNA-based typing.
42. Andrade RJ, Lucena MI, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R, Fernandez MC, Pelaez G, Romero M, Corpas R, Duran JA et al: HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology (2004) 39(6):1603-1612. Description of a study carried out on a large number of patients (n = 140) having a definitive diagnosis of DILI. The data demonstrate that certain HLA alleles are associated with specific clinical manifestations of the disease.
43. Pirmohamed M, Lin K, Chadwick D, Park BK: TNF-α promoter region gene polymorphisms in carbamazeplne-hypersensitive patients. Neurology (2001) 56(7):890-896. Demonstrates that patients with serious hypersensitivity reactions caused by carbamazepine, have a higher frequency of a variant allele of TNFα.
44. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, Caldwell J, Day CP: Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology (2004) 39(5):1430-1440. Demonstrates that polymorphisms, resulting in low IL-10 and high IL-4 levels, may contribute to an increased antibody production observed in patients with diclofenac-induced DILI.
45. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL: Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology (2000) 31(1):201-206.
46. Riley TR 3rd, Smith JP: Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series. Am J Gastroenterol (1998) 93(9):1563-1565.
47. Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA, Cramp ME: Acute liver failure associated with antiretroviral treatment for HIV: A report of six cases. J Hepatol (2002) 36(2):295-301.